第二代和第三代 ALK 酪氨酸激酶抑制剂治疗 ALK 阳性晚期非小细胞肺癌的真实世界治疗排序和有效性"[Lung Cancer 195 (2024) 107919]的更正。

IF 4.5 2区 医学 Q1 ONCOLOGY
Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, Stephen V Liu, Barbara Melosky, Devin Abrahami, Benjamin Li, Despina Thomaidou, Kirsten Duncan, Stan Krulewicz, Martin Rupp, Jessica J Lin
{"title":"第二代和第三代 ALK 酪氨酸激酶抑制剂治疗 ALK 阳性晚期非小细胞肺癌的真实世界治疗排序和有效性\"[Lung Cancer 195 (2024) 107919]的更正。","authors":"Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, Stephen V Liu, Barbara Melosky, Devin Abrahami, Benjamin Li, Despina Thomaidou, Kirsten Duncan, Stan Krulewicz, Martin Rupp, Jessica J Lin","doi":"10.1016/j.lungcan.2024.108000","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to \\\"Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer\\\" [Lung Cancer 195 (2024) 107919].\",\"authors\":\"Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, Stephen V Liu, Barbara Melosky, Devin Abrahami, Benjamin Li, Despina Thomaidou, Kirsten Duncan, Stan Krulewicz, Martin Rupp, Jessica J Lin\",\"doi\":\"10.1016/j.lungcan.2024.108000\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":18129,\"journal\":{\"name\":\"Lung Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.lungcan.2024.108000\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.lungcan.2024.108000","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919].
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Lung Cancer
Lung Cancer 医学-呼吸系统
CiteScore
9.40
自引率
3.80%
发文量
407
审稿时长
25 days
期刊介绍: Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信